Cancer Chemotherapy | Agenda Bookshop Skip to content

cancer

Age Group_Uncategorized
Age Group_Uncategorized
anticancer agent
automatic-update
B01=Gary S. Goldberg
B01=Rachel Airley
bioinformatics
cancer therapy
Category1=Non-Fiction
Category=PN
chemotherapy
clinical oncology
COP=United Kingdom
Delivery_Delivery within 10-20 working days
diagnosis
disease
drug
drug design
drug development
eq_isMigrated=2
eq_non-fiction
eq_science
health
Language_English
medical
medicine
molecular biology
oncology
PA=Available
pharmacology
prevention
Price_€50 to €100
PS=Active
softlaunch
theranostics

Cancer Chemotherapy

English

Provides a clear and accessible summary of all stages and aspects of the discovery, design, development, validation and clinical use of anticancer drugs

This new edition provides an update on the current state of the art of cancer chemotherapy and clinical practice and presents new pipeline anticancer agents and promising therapeutic strategies that are emerging alongside new breakthroughs in cancer biology. Its unique approach enables students to gain an understanding of the pathological, physiological, and molecular processes governing malignancy, while also introducing the role of health professionals and scientists in the research and treatment of cancer.

Invaluable for its clarity and accessibility, Cancer Chemotherapy: Basic Science to the Clinic, 2nd Edition offers complete coverage of the scientific and clinical aspects of the creation, development, and administration of drugs or drug regimens used in the treatment of the disease. Chapters look at: cancer epidemiology and histopathology; carcinogenesis; current research; tumor hypoxia; antiangiogenic and antivascular agents; protein kinase and Ras blockers; new targets associated with development such as Hedgehog and Wnt signaling; stem cells; immunotherapy and oncolytic viruses; and more.

  • Presents a clear, accessible, and comprehensive approach to cancer chemotherapy from basic science to clinical practice
  • Offers a major update that reflects the latest developments in personalized chemotherapy
  • Provides in-depth coverage of advances in biomarker diagnostics
  • Includes new chapters/sections on bioinformatics and the ‘omic sciences’; pharmaceutical strategies used to achieve tumor-selective drug delivery; and cancer cell autophagy
  • Combines descriptions of both clinical protocol and explanations of the drug design process in one self-contained book
  • Features numerous diagrams and illustrations to enhance reader understanding

Aimed at upper undergraduate, graduate, and medical students, Cancer Chemotherapy: Basic Science to the Clinic, 2nd Edition is also an excellent reference for health professional, especially clinicians specializing in Clinical Oncology, and their patients who want to gain an understanding of cancer and available treatment options.

See more
€65.99

cancerAge Group_Uncategorizedanticancer agentautomatic-updateB01=Gary S. GoldbergB01=Rachel Airleybioinformaticscancer therapyCategory1=Non-FictionCategory=PNchemotherapyclinical oncologyCOP=United KingdomDelivery_Delivery within 10-20 working daysdiagnosisdiseasedrugdrug designdrug developmenteq_isMigrated=2eq_non-fictioneq_sciencehealthLanguage_Englishmedicalmedicinemolecular biologyoncologyPA=AvailablepharmacologypreventionPrice_€50 to €100PS=Activesoftlaunchtheranostics

Delivery/Collection within 10-20 working days
Product Details
  • Weight: 635g
  • Dimensions: 173 x 244mm
  • Publication Date: 02 Apr 2020
  • Publisher: John Wiley and Sons Ltd
  • Publication City/Country: GB
  • Language: English
  • ISBN13: 9781118963852

About

GARY S. GOLDBERG, PhD, is an Associate Professor at the School of Osteopathic Medicine, Rowan University, Stratford, NJ, USA.

RACHEL AIRLEY, MRes, PhD, MRPharmS, FHEA, is a Community Pharmacist and former Lecturer in Pharmacology and Cancer Sciences, Manchester, UK.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept